Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1982 Jul;22(1):47–50. doi: 10.1128/aac.22.1.47

Moxalactam pharmacokinetics in children.

M F Romagnoli, K Flynn, G R Siber, D A Goldmann
PMCID: PMC183672  PMID: 6214997

Abstract

We measured the serum concentrations of moxalactam in 10 children receiving antibiotic prophylaxis for surgery and in 18 children treated for documented or suspected infections. Moxalactam was administered intravenously at a dose of 50 mg/kg every 8 h. After the first dose in 28 patients, mean moxalactam concentrations 5 min, 30 min, 2 h, and 8 h after infusion were 257, 177, 82.2, and 17.5 micrograms/ml, respectively. The mean half-life (T 1/2) was 2.44 h (range: 0.55 to 7.96 h). The mean distribution volume (VD) was 0.30 liters per kg. No significant accumulation was observed with multiple doses. Prophylactic and therapeutic groups had similar serum levels, T 1/2, and VD. The five infants less than 1 year of age had a lower mean 30-min level (P less than 0.01), larger VD (P less than 0.001) and longer T 1/2 (P less than 0.025) than the children older than 1 year. A dose of 50 mg/kg produced 30-min levels in excess of 64 microgram/ml in all patients studied, but 8-h trough levels were below the minimal inhibitory concentrations breakpoint of 17 mg/ml in 32% of patients.

Full text

PDF
47

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aronoff G. R., Sloan R. S., Mong S. A., Luft F. C., Kleit S. A. Moxalactam pharmacokinetics during hemodialysis. Antimicrob Agents Chemother. 1981 Apr;19(4):575–577. doi: 10.1128/aac.19.4.575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bauer A. W., Kirby W. M., Sherris J. C., Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966 Apr;45(4):493–496. [PubMed] [Google Scholar]
  3. Borobio M. V., Aznar J., Jimenez R., Garcia F., Perea E. J. Comparative in vitro activity of 1-oxa-beta-lactam (LY127935) and cefoperazone with other beta-lactam antibiotics against anaerobic bacteria. Antimicrob Agents Chemother. 1980 Feb;17(2):129–131. doi: 10.1128/aac.17.2.129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Estey E. H., Weaver S. S., Ho D. H., Bodey G. P. Clinical pharmacology of moxalactam in patients with malignant disease. Antimicrob Agents Chemother. 1981 Apr;19(4):639–644. doi: 10.1128/aac.19.4.639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Greenblatt D. J., Koch-Weser J. Clinical pharmacokinetics (second of two parts). N Engl J Med. 1975 Nov 6;293(19):964–970. doi: 10.1056/NEJM197511062931905. [DOI] [PubMed] [Google Scholar]
  6. Hall W. H., Opfer B. J., Gerding D. N. Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli. Antimicrob Agents Chemother. 1980 Feb;17(2):273–279. doi: 10.1128/aac.17.2.273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jorgensen J. H., Crawford S. A., Alexander G. A. In vitro activities of cefotaxime and moxalactam (LY127935) against Haemophilus influenzae. Antimicrob Agents Chemother. 1980 Mar;17(3):516–517. doi: 10.1128/aac.17.3.516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jorgensen J. H., Crawford S. A., Alexander G. A. In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli. Antimicrob Agents Chemother. 1980 Jun;17(6):937–942. doi: 10.1128/aac.17.6.937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kaplan S. L., Mason E. O., Jr, Garcia H., Kvernland S. J., Loiselle E. M., Anderson D. C., Mintz A. A., Feigin R. D. Pharmacokinetics and cerebrospinal fluid penetration of moxalactam in children with bacterial meningitis. J Pediatr. 1981 Jan;98(1):152–157. doi: 10.1016/s0022-3476(81)80562-8. [DOI] [PubMed] [Google Scholar]
  10. Landesman S. H., Corrado M. L., Cherubin C. C., Gombert M., Cleri D. Diffusion of a new beta-lactam (LY 127935) into cerebrospinal fluid. Implications for therapy of gram-negative bacillary meningitis. Am J Med. 1980 Jul;69(1):92–98. doi: 10.1016/0002-9343(80)90505-7. [DOI] [PubMed] [Google Scholar]
  11. Loo J. C., Riegelman S. Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion. J Pharm Sci. 1970 Jan;59(1):53–55. doi: 10.1002/jps.2600590107. [DOI] [PubMed] [Google Scholar]
  12. Neu H. C., Aswapokee N., Fu K. P., Aswapokee P. Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds. Antimicrob Agents Chemother. 1979 Aug;16(2):141–149. doi: 10.1128/aac.16.2.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Parsons J. N., Romano J. M., Levison M. E. Pharmacology of a new 1-oxa-beta-lactam (LY127935) in normal volunteers. Antimicrob Agents Chemother. 1980 Feb;17(2):226–228. doi: 10.1128/aac.17.2.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Schaad U. B., McCracken G. H., Jr, Threlkeld N., Thomas M. L. Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants. J Pediatr. 1981 Jan;98(1):129–136. doi: 10.1016/s0022-3476(81)80559-8. [DOI] [PubMed] [Google Scholar]
  15. Scheld W. M., Spyker D. A., Donowitz G. R., Bolton W. K., Sande M. A. Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects. Antimicrob Agents Chemother. 1981 Apr;19(4):613–619. doi: 10.1128/aac.19.4.613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Thirumoorthi M. C., Buckley J. A., Aravind M. K., Kauffman R. E., Dajani A. S. Diffusion of moxalactam into the cerebrospinal fluid in children with bacterial meningitis. J Pediatr. 1981 Dec;99(6):975–979. doi: 10.1016/s0022-3476(81)80036-4. [DOI] [PubMed] [Google Scholar]
  17. Yoshida T., Matsuura S., Mayama M., Kameda Y., Kuwahara S. Moxalactam (6059-S), a novel 1-oxa-beta-lactam with an expanded antibacterial spectrum: laboratory evaluation. Antimicrob Agents Chemother. 1980 Mar;17(3):302–312. doi: 10.1128/aac.17.3.302. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES